Last reviewed · How we verify
Rimegepant/BHV3000 (rimegepant-bhv3000)
Rimegepant/BHV3000 is a marketed drug by Pfizer Inc. for the acute treatment of migraine with or without aura in adults and prevention of migraine in adults. It has 17 trials but no publications. The commercial significance and pipeline developments are not specified. Rimegepant/BHV3000 is a small molecule drug. It is used for its pharmacological class and modality. The novelty of the drug is not specified.
At a glance
| Generic name | rimegepant-bhv3000 |
|---|---|
| Sponsor | Pfizer |
| Drug class | pharmacological class not specified |
| Target | calcitonin gene-related peptide receptor (CGRPR) |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Acute treatment of migraine with or without aura in adults
- Prevention of migraine in adults
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole)
- P-glycoprotein inducers (e.g., rifampin, St. John's Wort)
- Strong CYP3A inhibitors (e.g., itraconazole, clarithromycin)
- Strong CYP3A inducers (e.g., rifampin, St. John's Wort)
- CYP3A substrates (e.g., midazolam, triazolam)
- CYP2C19 substrates (e.g., omeprazole, lansoprazole)
Key clinical trials
- Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects (PHASE3)
- Randomized Study in Children and Adolescents With Migraine: Acute Treatment (PHASE3)
- A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects. (PHASE3)
- Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only) (PHASE3)
- Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention (PHASE4)
- Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis (PHASE3)
- Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only) (PHASE3)
- A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rimegepant/BHV3000 CI brief — competitive landscape report
- Rimegepant/BHV3000 updates RSS · CI watch RSS
- Pfizer portfolio CI